MA54227A - Méthodes de traitement de la fibrose kystique - Google Patents

Méthodes de traitement de la fibrose kystique

Info

Publication number
MA54227A
MA54227A MA054227A MA54227A MA54227A MA 54227 A MA54227 A MA 54227A MA 054227 A MA054227 A MA 054227A MA 54227 A MA54227 A MA 54227A MA 54227 A MA54227 A MA 54227A
Authority
MA
Morocco
Prior art keywords
cystic fibrosis
treatment methods
fibrosis treatment
cystic
methods
Prior art date
Application number
MA054227A
Other languages
English (en)
Other versions
MA54227B1 (fr
Inventor
David M Altshuler
Corey Don Anderson
Bartlomiej Borek
Weichao George Chen
Jeremy J Clemens
Thomas Cleveland
Timothy Richard Coon
Bryan Frieman
Peter Grootenhuis (Deceased)
Ruah Sara Sabina Hadida
Brian J Hare
Reshma Kewalramani
Jason Mccartney
Mark Thomas Miller
Prasuna Paraselli
Fabrice Pierre
Sarah M Robertson
Patrick R Sosnay
Sara E Swift
Goor Fredrick Van
Tim Young
Jinglan Zhou
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68808572&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA54227(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MA54227A publication Critical patent/MA54227A/fr
Publication of MA54227B1 publication Critical patent/MA54227B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA54227A 2018-11-14 2019-11-13 Méthodes de traitement de la fibrose kystique MA54227B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862767202P 2018-11-14 2018-11-14
PCT/US2019/061171 WO2020102346A1 (fr) 2018-11-14 2019-11-13 Méthodes de traitement de la fibrose kystique

Publications (2)

Publication Number Publication Date
MA54227A true MA54227A (fr) 2021-09-22
MA54227B1 MA54227B1 (fr) 2023-03-31

Family

ID=68808572

Family Applications (1)

Application Number Title Priority Date Filing Date
MA54227A MA54227B1 (fr) 2018-11-14 2019-11-13 Méthodes de traitement de la fibrose kystique

Country Status (26)

Country Link
US (1) US20220047564A1 (fr)
EP (2) EP4218754B1 (fr)
AU (1) AU2019381750B2 (fr)
BR (1) BR112021009145A2 (fr)
CA (1) CA3123578A1 (fr)
CL (1) CL2021001248A1 (fr)
CO (1) CO2021007447A2 (fr)
DK (1) DK3880197T3 (fr)
EA (1) EA202191361A1 (fr)
ES (1) ES2943126T3 (fr)
FI (2) FI3880197T3 (fr)
FR (1) FR25C1049I1 (fr)
HR (1) HRP20230272T1 (fr)
HU (2) HUE061686T2 (fr)
IL (1) IL282988B2 (fr)
LT (2) LT3880197T (fr)
MA (1) MA54227B1 (fr)
MD (1) MD3880197T3 (fr)
NL (1) NL301357I2 (fr)
NO (1) NO2025052I1 (fr)
PL (1) PL3880197T3 (fr)
PT (1) PT3880197T (fr)
RS (1) RS64192B9 (fr)
SI (1) SI3880197T1 (fr)
SM (1) SMT202300102T1 (fr)
WO (1) WO2020102346A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202004264VA (en) * 2017-12-01 2020-06-29 Vertex Pharma Processes for making modulators of cystic fibrosis transmembrane conductance regulator
EP3752510B1 (fr) 2018-02-15 2022-12-07 Vertex Pharmaceuticals Incorporated Macrocycles utilisés en tant que modulateurs du régulateur de la conductance transmembranaire de fibrose kystique, compositions pharmaceutiques de ceux-ci, leur utilisation dans le traitement de la fibrose kystique et procédé de fabrication associé
TWI848092B (zh) 2019-04-03 2024-07-11 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白調節劑
KR20220064366A (ko) 2019-08-14 2022-05-18 버텍스 파마슈티칼스 인코포레이티드 Cftr 조절제의 결정질 형태
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
MX2022001827A (es) * 2019-08-14 2022-06-09 Vertex Pharma Moduladores del regulador de conductancia transmembrana de la fibrosis quistica.
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CA3188787A1 (fr) 2020-08-13 2022-02-17 Vertex Pharmaceuticals Incorporated Formes cristallines de modulateurs de cftr
US12324802B2 (en) 2020-11-18 2025-06-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CA3204725A1 (fr) * 2020-12-10 2022-06-16 Vertex Pharmaceuticals Incorporated Methodes de traitement de la mucoviscidose
CN116829148A (zh) * 2020-12-10 2023-09-29 弗特克斯药品有限公司 治疗囊性纤维化的方法
JP2025506382A (ja) 2022-02-03 2025-03-11 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症の治療方法
KR20240155228A (ko) 2022-02-03 2024-10-28 버텍스 파마슈티칼스 인코포레이티드 (6a,12a)-17-아미노-12-메틸-6,15-비스(트리플루오로메틸)-13,19-디옥사-3,4,18-트리아자트리시클로[12.3.1.12,5]노나데카-1(18),2,4,14,16-펜타엔-6-올의 결정질 형태를 제조하는 방법
AU2023218262A1 (en) 2022-02-08 2024-08-22 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CA3253026A1 (fr) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la fibrose kystique
US20250340568A1 (en) 2022-05-16 2025-11-06 Vertex Pharmaceuticals Incorporated Solid forms of a macrocyclic compounds as cftr modulators and their preparation
WO2025166342A1 (fr) 2024-02-04 2025-08-07 Vertex Pharmaceuticals Incorporated Combinaison de vanzacaftor, de tezacaftor et de deutivacaftor destinée à être utilisée dans le traitement de la fibrose kystique
EP4648753B1 (fr) 2024-02-07 2026-02-18 Vertex Pharmaceuticals Incorporated Compositions pour le traitement de maladies médiées par cftr

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04004657A (es) 2001-11-14 2004-08-13 Teva Pharma Formas amorfas y cristalinas de potasio de losartan y proceso para su preparacion.
ES2377840T3 (es) 2006-05-12 2012-04-02 Vertex Pharmaceuticals, Inc. Composiciones de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida
LT3345625T (lt) 2008-08-13 2021-02-10 Vertex Pharmaceuticals Incorporated Farmacinė kompozicija ir jos vartojimas
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
AU2009296271A1 (en) 2008-09-29 2010-04-01 Vertex Pharmaceuticals Incorporated Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
SMT202100051T1 (it) 2010-03-25 2021-03-15 Vertex Pharma Dispersione solida di una forma amorfa di (r)-1-(2,2-difluorobenzo[d][1,3]diossol-5-il)-n-(1-(2,3-diidrossipropil)-6-fluoro-2-(1-idrossi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropan-carbossamide
BR112012026255A2 (pt) 2010-04-07 2017-03-14 Vertex Pharma composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas
AU2011242452A1 (en) 2010-04-22 2012-11-08 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
RU2745977C2 (ru) 2010-04-22 2021-04-05 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
CA2809263A1 (fr) 2010-08-27 2012-03-01 Eleni Dokou Composition pharmaceutique et ses administrations
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的組成物およびその投与
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
SMT202500078T1 (it) 2012-11-02 2025-03-12 Vertex Pharma Composizioni farmaceutiche per il trattamento di malattie mediate da cftr
SG10201913575VA (en) 2014-04-15 2020-02-27 Vertex Pharma Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
EP3798214B1 (fr) * 2014-10-06 2022-09-14 Vertex Pharmaceuticals Incorporated Modulateurs de régulateur de conductance transmembranaire de la fibrose kystique
US20180353500A1 (en) 2015-09-21 2018-12-13 Vertex Pharmaceuticals (Europe) Limited Administration of deuterated cftr potentiators
SG10201913595YA (en) 2016-09-30 2020-02-27 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2018080591A1 (fr) 2016-10-27 2018-05-03 Vertex Pharmaceuticals (Europe) Limited Procédés de traitement avec des potentialisateurs cftr deutérés
WO2019018353A1 (fr) * 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la fibrose kystique
BR112020000941A2 (pt) * 2017-07-17 2020-07-21 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
TWI810243B (zh) * 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3752510B1 (fr) 2018-02-15 2022-12-07 Vertex Pharmaceuticals Incorporated Macrocycles utilisés en tant que modulateurs du régulateur de la conductance transmembranaire de fibrose kystique, compositions pharmaceutiques de ceux-ci, leur utilisation dans le traitement de la fibrose kystique et procédé de fabrication associé

Also Published As

Publication number Publication date
SI3880197T1 (sl) 2023-04-28
ES2943126T9 (en) 2025-10-09
EP3880197B9 (fr) 2025-07-02
EA202191361A1 (ru) 2021-08-11
SMT202300102T1 (it) 2023-05-12
FIC20253012I1 (fi) 2025-12-04
MD3880197T2 (ro) 2023-08-31
DK3880197T3 (da) 2023-03-27
US20220047564A1 (en) 2022-02-17
MA54227B1 (fr) 2023-03-31
RS64192B1 (sr) 2023-06-30
NO2025052I1 (no) 2025-12-04
HUE061686T2 (hu) 2023-08-28
EP3880197A1 (fr) 2021-09-22
LT3880197T (lt) 2023-05-10
WO2020102346A1 (fr) 2020-05-22
MD3880197T3 (ro) 2025-12-31
CL2021001248A1 (es) 2021-11-26
PT3880197T (pt) 2023-05-09
IL282988B2 (en) 2025-11-01
BR112021009145A2 (pt) 2021-08-10
HUS2500048I1 (hu) 2025-12-28
AU2019381750B2 (en) 2025-08-07
EP3880197B1 (fr) 2023-02-22
EP4218754A3 (fr) 2023-08-16
PL3880197T3 (pl) 2023-07-31
CA3123578A1 (fr) 2020-05-20
EP4218754B1 (fr) 2026-03-25
CO2021007447A2 (es) 2021-12-10
HRP20230272T1 (hr) 2023-04-28
NL301357I2 (nl) 2026-02-05
AU2019381750A1 (en) 2021-06-24
FI3880197T3 (fi) 2023-05-04
IL282988B1 (en) 2025-07-01
FR25C1049I1 (fr) 2026-01-16
ES2943126T3 (es) 2023-06-09
EP4218754A2 (fr) 2023-08-02
IL282988A (en) 2021-06-30
RS64192B9 (sr) 2025-10-31
LTPA2025543I1 (fr) 2026-01-12

Similar Documents

Publication Publication Date Title
FR25C1049I1 (fr) Méthodes de traitement de la fibrose kystique
MA49631A (fr) Méthodes de traitement de la fibrose kystique
MA54105A (fr) Méthodes de traitement de la fibrose kystique
EP3813808A4 (fr) Méthodes de traitement de la toxicomanie
MA47558A (fr) Traitement de la fibrose
EP3752161A4 (fr) Méthodes de traitement de la fibrose
EP3645145A4 (fr) Purification d'oligosaccharides
HRP20181692T1 (hr) Liječenje fibroze
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
EP3658139A4 (fr) Méthodes de traitement de maladies hépatiques
EP3773633A4 (fr) Méthodes de traitement de glioblastomes
EP3946345A4 (fr) Méthodes de traitement de la douleur neuropathique
EP3630101A4 (fr) Méthodes de traitement de maladies
MA53882A (fr) Méthodes de traitement de la sclérose en plaques
EP3606531A4 (fr) Méthodes de traitement du cancer
EP3634422A4 (fr) Méthodes de traitement de la leucodystrophie
EP3328384A4 (fr) Traitement de la fibrose
EP3599983A4 (fr) Endoscopes et méthodes de traitement
EP3787625A4 (fr) Méthodes de traitement du cancer
EP3852816A4 (fr) Méthodes de traitement de cancer
EP3713576A4 (fr) Méthodes de traitement du cancer
EP3873528A4 (fr) Traitement de rasopathie
BR112017011897A2 (pt) métodos de tratamento da fibrose
IL281839A (en) Treatment methods
IL281792A (en) Treatment methods